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Accurate prediction of response to
endocrine therapy in breast cancer
patients: current and future biomarkers
Cigdem Selli1,3, J. Michael Dixon2 and Andrew H. Sims1*
Abstract
Approximately 70% of patients have breast cancers that are oestrogen receptor alpha positive (ER+) and are therefore
candidates for endocrine treatment. Many of these patients relapse in the years during or following completion of
adjuvant endocrine therapy. Thus, many ER+ cancers have primary resistance or develop resistance to endocrine
therapy during treatment. Recent improvements in our understanding of how tumours evolve during treatment with
endocrine agents have identified both changes in gene expression and mutational profiles, in the primary cancer as
well as in circulating tumour cells. Analysing these changes has the potential to improve the prediction of which
specific patients will respond to endocrine treatment. Serially profiled biopsies during treatment in the neoadjuvant
setting offer promise for accurate and early prediction of response to both current and novel drugs and allow
investigation of mechanisms of resistance. In addition, recent advances in monitoring tumour evolution through
non-invasive (liquid) sampling of circulating tumour cells and cell-free tumour DNA may provide a method to detect
resistant clones and allow implementation of personalized treatments for metastatic breast cancer patients. This review
summarises current and future biomarkers and signatures for predicting response to endocrine treatment, and
discusses the potential for using approved drugs and novel agents to improve outcomes. Increased prediction
accuracy is likely to require sequential sampling, utilising preoperative or neoadjuvant treatment and/or liquid biopsies
and an improved understanding of both the dynamics and heterogeneity of breast cancer.
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Background
Breast cancer is the most common cancer in women and
second most common cancer worldwide [1]. A heteroge-
neous and dynamic disease, breast cancer exhibits unique
acquired somatic mutations and gene expression changes
that underpin the two main mortality factors: disease recur-
rence and drug resistance. Resistance to endocrine therapy
can occur at disease inception (de novo or intrinsic resist-
ance) or develop during treatment (acquired resistance),
and various molecular resistance mechanisms have been
proposed [2]. Breast cancer is divided into several subtypes
with distinct histological, genomic and transcriptomic pro-
files, outcomes, and responses to therapy [3]. Fundamen-
tally, expression of oestrogen receptor alpha (ER) classifies
patients simply as either having ER-positive (ER+) or ER-
negative disease, the former representing approximately
70% of patients. However, its expression is heterogeneous
and its predictive value is limited since only up to 50–70%
of ER+ patients respond clinically to neoadjuvant endocrine
therapy [4, 5] indicating the need for biomarkers that pre-
dict those likely to respond. In addition, responders exhibit
considerable heterogeneity in their responses to endocrine
agents and as many as 40–50% of ER+ patients relapse in
the adjuvant setting [6]. Whilst adjuvant endocrine treat-
ment reduces 5-year recurrence rates significantly, it has
less effect on 5-year mortality rates. For instance, 5 years of
tamoxifen treatment reduces mortality by 25% of its relative
reduction of recurrences [7].
Recently the use of endocrine therapy in the neoadjuvant
setting has allowed clinicians to detect patients that benefit
from treatment over a short-term period by simultaneously
monitoring tumour volume. In addition to the short-term
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benefit, neoadjuvant treatment response is reflective of
adjuvant benefit [8] and further allows established or novel
drugs to be tested, either alone or in combination [9]. This
can allow rapid introduction of efficient novel therapies as
well as predictive biomarkers into the clinic. Although
assessment or biopsy of the primary tumour during treat-
ment may improve response prediction, this approach
could be combined with non-invasive long-term follow-up
to ensure that treatment benefit continues (Fig. 1). Potential
plasma biomarkers such as circulating tumour cells (CTCs)
and cell-free DNA may provide similar data on long-term
efficacy of endocrine treatments.
In this review, we discuss the current and potential future
of endocrine treatment response prediction and biomarkers
for individualization of breast cancer therapy in patients
with ER+ cancers. Combining endocrine treatment with
emerging drugs is also discussed. Current conventional
biomarker and drug discovery approaches using hete-
rogeneous patient populations should be replaced with
more time-efficient and individualised designs. Monitoring
treatment response by comparing before treatment and on-
treatment blood and biopsy samples should allow imple-
mentation of individualised endocrine therapy.
Targeted endocrine treatment of breast cancer
Tamoxifen was the first selective oestrogen receptor
modulator (SERM) used clinically and is still widely
prescribed in pre-menopausal women; it antagonistically
regulates ER in breast and brain tissue but is an agonist in
the uterus and liver. Aromatase inhibitors (AI), including
letrozole, anastrozole, and exemestane, block oestrogen
production by inhibition of aromatase in both peripheral
tissues and in the cancer, and are effective only for post-
menopausal women in whom the major source of
oestrogen is peripheral tissues such as adipose tissue and
the breast. The selective oestrogen receptor downregula-
tor (SERD) fulvestrant has been shown to be as effective
as anastrozole but with a significantly longer time to
progression when used as first-line endocrine therapy in
post-menopausal women with advanced ER+ breast can-
cer in the initial analysis of the FIRST trial [10]. Recent
randomized studies have demonstrated extended overall
survival with first-line [11] and extended progression-free
survival with second-line fulvestrant when compared to
anastrozole (phase III FALCON trial).
Targeted endocrine treatments for ER+ breast cancer have
been available for over 30 years and have had a significant
impact in improving mortality rates [7], although inhibiting
ER signalling is not effective in all patients with ER+ cancers.
Many ER+ breast cancer patients that initially benefit from
first-line endocrine therapy go on to relapse as a conse-
quence of the cancer developing endocrine resistance.
Novel approaches to overcome endocrine
treatment resistance
A number of promising agents aimed at overcoming endo-
crine resistance by targeting signalling pathways are cur-
rently under clinical investigation [12]. Detailed information
regarding the molecular mechanisms of endocrine resistance
can be found in a recent review by Clarke et al. [2].
In ER+ disease, loss of ER expression is not a common
resistance mechanism and occurs in only a limited number
Fig. 1 A combined approach for individualised prediction of endocrine treatment response. Profiling of biopsy samples during neoadjuvant drug
treatment may help to match drugs to patients and to predict treatment response. Neoadjuvant assessment should be combined with long-term
follow-up of individual tumour changes acquired during treatment via non-invasive (liquid biopsy) sampling. Profiling circulating tumour cells (CTCs)
and circulating tumour DNA (ctDNA) can be used to monitor continuous benefit from adjuvant treatment and to detect disease progression. In future
practice, a combination of these approaches with predictive biomarkers would provide a more accurate prediction of endocrine therapy response
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of patients, and most tumours still respond to second- or
third-line anti-oestrogen therapies. More commonly, resist-
ance is facilitated by sequential upregulation of pathways
downstream of ERα such as phosphoinositide-3-kinase/
AKT/mammalian target of rapamycin (PI3K/AKT/mTOR)
signalling. One future aim is to restore sensitivity to
endocrine therapy or prevent resistance outright by using
combined endocrine agents or combining endocrine agents
together with novel drugs. Combinations of current drugs,
such as fulvestrant and anastrozole, are being tested in the
metastatic setting but the results so far have not clearly
shown an advantage for the combination [13, 14], and
potentially highlight the need for new drug combinations
to be investigated. Other potential candidate combination
includes endocrine agents together with agents that target
the cell cycle, although the efficacy of this combination
depends on the individual molecular profile of the cancer.
Enhanced toxicity and the cost of combined therapy are
limitations that must be overcome. Given the inherent
heterogeneity of ER+ disease, individualising therapy is
proving difficult without predictive biomarkers. Whether all
patients require the combination is also unclear, although
there is optimism that outcomes for patients whose cancers
continue to proliferate on endocrine therapy will be im-
proved by these combinations [15].
ER signalling exhibits crosstalk with various growth fac-
tor receptor signalling pathways that promote ligand-
independent activation of ER. However, current clinical
studies do not support the additional clinical benefit of
combining endocrine therapy with growth factor inhibitors
such as gefitinib [16], bevacizumab [17], and ganitumab in
post-menopausal ER+ locally advanced or metastatic breast
cancer patients. Although these trials were performed in a
specific subpopulation of patients based on current
biomarkers and clinical criteria, these subgroups are not
homogeneous. It could be that the negative results resulted
from patient heterogeneity and that some individual pa-
tients did benefit, again emphasising the need for improved
biomarkers to predict those who may benefit from specific
growth factor inhibitors.
The PI3K/AKT/mTOR pathway is downstream of ER
and other growth factor receptor signalling pathways and
its hyperactivation has been reported in resistance to both
endocrine and trastuzumab therapy [4]. Several agents tar-
geting PI3K and AKT are currently being studied in clinical
trials. Mutations in PIK3CA, AKT, and PTEN, an endogen-
ous inhibitor of PI3K signalling that limits cell proliferation,
have been suggested to predict response to therapy. In a
study we performed, PIK3CA mutation status did not
change during development of endocrine resistance and so
is not a mechanism of resistance, but mutation status at
diagnosis could be used to determine who might benefit
from a PI3K inhibitor either as adjuvant or at relapse and
development of subsequent metastatic disease [18].
Downstream of PI3K, mTOR appears to be a more prom-
ising drug target. The cumulative benefit of combination
therapy with letrozole and the first mTOR inhibitor everoli-
mus has been demonstrated using the neoadjuvant setting
[19]. Dramatic downregulation of phospho-S6, a down-
stream effector of mTOR, was observed only in everolimus-
treated patients, supporting a potential predictive role of
phospho-S6 in response to mTOR inhibitors [19].
Downstream of all the pathways outlined above is the cell
cycle machinery. Cyclin D1, which activates cell cycle re-
entry via cyclin-dependent kinase (CDK)4 and CDK6 is the
transcriptional target of ER and growth factor pathways.
Oral selective CDK4/6 inhibitors (palbociclib, ribociclib,
and abemaciclib) in combination with endocrine therapies
are under investigation [20], and potential predictive
markers of the treatment benefit other than ER positivity
are also being investigated. In recent clinical trials that
demonstrated improved clinical benefit with CDK4/6 inhib-
itors, cyclin D1 amplification and p16 loss were not signifi-
cant predictors of benefit, and ER status was the most
effective predictive marker in identifying patients likely to
respond to first-line CDK4/6 inhibitor therapy [21, 22].
The histone deacetylase (HDAC) inhibitors panobinostat,
vorinostat, and entinostat are other new drugs being inves-
tigated in ER+ breast cancer. Patients could potentially be
stratified by assessing breast cancer-specific HDAC enzyme
expression and acetylation levels of target proteins before
and after treatment [23].
Old drugs with new applications
In addition to novel drugs, currently approved drugs with
potential anti-tumour activities are being investigated in
patients with ER+ disease prevention and treatment.
Metformin, used to treat type II diabetes, and statins, used
for the treatment of hyperlipidaemia, are examples. Anti-
tumour activities of metformin as monotherapy [24] and
its synergistic potential in combination with neoadjuvant
letrozole [25] are currently being studied. Although the
anti-tumour mechanism of action of metformin is not yet
clear [24], its anti-tumour effects in breast cancer are sug-
gested to be via an indirect pathway by decreasing both
insulin plasma levels and inhibiting downstream PI3K and
mitogen-activated protein kinase (MAPK) signalling.
Based on the results from a recent window-of-opportunity
study, serum insulin, tumour insulin receptor expression,
p-Akt, and Ki-67 are potential biomarkers of tumour met-
formin sensitivity [26].
Stable upregulation of cholesterol biosynthesis pathways
was recently determined in AI-resistant cells [27]. This is
consistent with epidemiological data showing that patients
with ER+ cancers who have high expression of cholesterol
biosynthesis pathways at diagnosis have shorter recurrence-
and metastatic-free survival, thus suggesting a predictive
role for cholesterol biosynthesis pathways in endocrine
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treatment response [27]. One study with a population of
patients with a mix of ER+ and ER-negative cancers failed
to show any correlation between response to simvastatin
and selected drug- and breast cancer risk-specific bio-
markers, serum concentrations of high-sensitivity C-
reactive protein, oestrogens, and fasting lipids [28]. Despite
this, further trials of specific subgroups of patients may
identify groups who benefit from this treatment and per-
haps also predictive biomarkers.
Based on the promising preclinical data [29], anti-
resorptive bone agents such as bisphosphonates and done-
sumab are under clinical investigation in metastatic breast
cancer. A recent meta-analysis of clinical trials shows that
adjuvant bisphosphonates improve breast cancer survival
by reducing breast cancer recurrence in the bone in post-
menopausal women but not pre-menopausal women [30],
possibly due to differential bone turnover rate and differ-
ences in bone microenvironment before and after the
menopause. Bone turnover markers released during bone
resorption, such as the carboxyterminal peptide of type I
collagen, may predict which patients are at increased risk of
bone relapse [31] as well as allowing monitoring of re-
sponse to anti-resorptive therapy.
In the future, novel drugs targeting critical molecular
pathways that exhibit crosstalk with ER will likely be used
in combination with endocrine therapy based on tumour-
specific profiles. Real-time monitoring of treatment re-
sponse may allow cancers that develop acquired muta-
tions in currently druggable targets to be identified and
allow patients to alter their treatment as appropriate.
Combinations of established and novel drugs currently in
clinical trials with their associated target molecules are
summarised in Fig. 2. Predicting which patients will bene-
fit from these combinations will be a major challenge.
Current predictive biomarkers of endocrine
treatment
Three biomarkers, ER, progesterone receptor (PR), and
human epidermal growth factor receptor 2 (HER2/ErbB2),
are currently measured both for diagnosis of disease sub-
type and as a guide to treatment. ERα presence is the best
predictor for endocrine treatment; however, patient re-
sponse remains heterogeneous. It is known that the ESR1
levels correlate with treatment outcome, with low levels of
ESR1 mRNA in the primary tumour being associated with
decreased tamoxifen benefit [32]. PR expression, which is
downstream of ER signalling and regulated by ER, is asso-
ciated with good prognosis, although its predictive role in
endocrine therapy response remains unclear. Benefit from
tamoxifen is similar in both PR-positive and PR-negative
Fig. 2 Drugs used in endocrine treatment of breast cancer. Schematic diagram of current and novel drugs currently in clinical trial with their
target signalling molecules. CDK cyclin-dependent kinase, E2 oestradiol-17 beta, EGFR epidermal growth factor receptor, ER oestrogen receptor,
HDAC histone deacetylase, HER2 human epidermal growth factor receptor, IGF-1R insulin-like growth factor-1 receptor, MAPK mitogen-activated
protein kinase, mTOR mammalian target of rapamycin, PI3K phosphoinositide-3-kinase, SERD selective oestrogen receptor degrader, SERM selective
oestrogen receptor modulator, T testosterone, VEGF vascular endothelial growth factor, VEGFR VEGF receptor
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patients [7]. On the other hand, the presence of PR and
quantitative levels have been shown to correlate signifi-
cantly with time to AI treatment failure in ER+ patients,
suggesting its predictive role in AI response [33]. How-
ever, PR status could not differentiate the relative benefit
of anastrozole over tamoxifen [34]. A functional crosstalk
between PR and ER, decreased PR expression linked with
altered ER chromatin binding and poor clinical outcome,
has been reported recently [35]. The third routinely used
biomarker, HER2, is a predictor of adverse outcome in
patients receiving adjuvant endocrine treatment. Not all
patients with ER+ HER2+ cancers relapse, and responses
to HER2-directed therapy are much less frequent in ER+
HER2+ cancers than ER– HER2+ cancers [36]. Nonethe-
less, a subgroup of patients with ER+ cancers that overex-
press HER2 are candidates for targeted anti-HER2 therapy
such as trastuzumab, pertuzumab, and lapatinib in com-
bination with chemotherapy.
Multigene signatures predict prognosis
Besides these well-established immunohistochemical
markers, an RNA-based multigene test that directly pre-
dicts patients who will effectively respond to endocrine
therapy has not yet made it to routine clinical practice.
Using individual patient-derived genomic information to
predict benefit is the underlying goal of individualised
therapy. This should allow matching the right drug with
the right patient. Microarray-based gene expression
analysis of cell lines and patient-derived primary samples
has been widely used to find drug response-related gene
signatures. Comparing different profiling approaches,
microarrays have been shown to be the most powerful in
predicting drug sensitivity in human breast cancer cell
lines (NCI-DREAM project) [37]. Advances in genomic
technology and bioinformatics analysis have led to the
molecular sub-classification of breast cancer with prog-
nostic implications and introduction of multigene assays
into the clinic. Based on gene expression analysis, ER+
breast cancer has been sub-classified into two main cate-
gories—luminal A and luminal B—the latter associated
with a poorer outcome [38]. Multigene expression assays
that are currently available in the clinic also help to pre-
dict prognosis. For instance, the Food and Drug Adminis-
tration (FDA)-approved Prosigna breast cancer gene
signature assay, based on the PAM50 intrinsic subtype
classification model [39], provides assessment of 10-year
risk of distant recurrence of post-menopausal ER+
patients. In addition, other multi-gene expression tests
such as Oncotype DX (21-gene signature), MammaPrint
(70-gene signature), and EndoPredictClin (a quantitative
RT-PCR-based assay of eight genes) are helpful in identify-
ing a subpopulation of ER+ patients with a low recurrence
risk who can potentially avoid chemotherapy or benefit
from extended adjuvant hormonal therapy. Recently, the
clinical utility of Oncotype DX has been validated pro-
spectively by identifying low-risk patients with ER+
HER2– cancers who do not benefit from adjuvant chemo-
therapy [40]. Although the multigene assays available
today are useful in predicting prognosis in terms of relapse
and risk stratification, their ability to predict endocrine
treatment efficacy has not been validated. To increase re-
sponse prediction accuracy using array profiling, dataset
and sample composition (i.e. non-tumour content) should
also be considered [41, 42].
Is accurate prediction possible?
Whilst prognostic factors correlate with expected disease
course, a predictive biomarker is associated with response
to a particular therapy and provides information on the
likely benefit from that treatment. Some biomarkers can
be both predictive and prognostic, such as ER status and
HER2 amplification. In addition, a biological tumour char-
acteristic can both be a therapeutic target and biomarker.
For clinical evaluation of cancer therapeutics, assessment
of tumour burden and disease progression are currently
used as endpoints in clinical trials. To standardize the evalu-
ation criteria used in clinical studies, the Response Evalu-
ation Criteria In Solid Tumours (RECIST) guidelines were
published [43]. Assessment of tumour volume reduction
using imaging can be an objective but sometimes insensitive
method because image resolution may not be good enough
to allow accurate measurements to be obtained. Tumour
burden is commonly assessed uni-dimensionally by mam-
mography and ultrasonography, although volumetric or
functional imaging tools such as magnetic resonance
imaging (MRI) may be more accurate. MRI is recommended
over mammography and computerised tomography in
assessing response in the neoadjuvant setting [43]. The
definition and assessment of outcomes in trials vary and in-
cludes time-to-progression, progression (recurrence/disease/
relapse)-free survival, and overall survival, making direct
comparison of results from different trials difficult.
One challenge in identifying predictive biomarkers using
conventional clinical trial design is the necessity for long-
term follow-up data. The neoadjuvant setting offers a po-
tential solution to this problem by allowing relatively quick
detection of patients that benefit from an intervention [44].
The accepted method of assessing response to neoadjuvant
chemotherapy response is pathological complete response
(pCR) rate defined by the absence of residual tumour
burden in the breast and associated axillary lymph nodes.
Pertuzumab received an accelerated FDA approval based
on meeting this criterion, in the absence of long-term data
in the neoadjuvant setting [9]. In a pooled analysis of neo-
adjuvant clinical trials, pCR was shown to correlate with
long-term clinical benefit [45]. However, correlation of pCR
with improved survival benefit was most evident in triple-
negative disease and HER2-positive cancer, but was not
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significant for patients with ER+ low-grade cancers [45].
Also, in practical terms, the molecular evaluation of re-
sponse is not feasible in pCR patients due to the unavail-
ability of tumour material following chemotherapy.
A further limitation of current clinical studies is the use
of pooled data analysis obtained from large heterogeneous
groups of patients. Even if clinical studies are performed
using specific patient subgroups, such as only ER+ and
HER2-negative patients, high degrees of molecular hetero-
geneity are still evident. The Signature Clinical Trial
Program, a modular phase II trial by Novartis, aims to
overcome drawbacks of traditional clinical trials by linking
targeted therapies to patients with pathway-activated tu-
mours. Further trials using specific patient subgroups with
specific mutations to target genes such as ER and PI3K
may help to more accurately identify predictive bio-
markers. In addition to inter-patient heterogeneity, intra-
tumour heterogeneity is another obstacle in effective
breast cancer treatment and response prediction. Breast
cancers can be composed of a dominant clone that
represents the primary tumour with minor quiescent sub-
clone(s) [46]. The only way to predict individual response
to therapy is the real-time profiling of tumour samples
from individual patients because of such a heterogeneous
and evolving disease profile. There is a real need to deter-
mine novel biomarkers on an individual basis that differ-
entiate patients that are most likely to respond or acquire
resistance to endocrine therapy. Accurate prediction is
not possible in the absence of biomarkers derived from
the individual characteristic of every tumour.
The neoadjuvant setting to predict endocrine
treatment response
Short-term pre-operative trials with specific groups of
patients have proved promising in identifying predictive
biomarkers of the efficacy of anti-cancer-targeted therap-
ies [47]. Early evidence of endocrine drug effectiveness
can be obtained in the pre-operative (neoadjuvant) setting
by profiling baseline and on-treatment biopsy samples
utilising the window-of-opportunity. This predictive
evidence acquired during short-term neoadjuvant therapy
can help to identify individual patients that will potentially
benefit from long-term adjuvant treatment enabling
personalized approaches. In the following section, we will
summarise the current neoadjuvant studies that have in-
vestigated prediction of endocrine treatment response.
The largest window-of-opportunity trial to date includes
over 4000 post-menopausal ER+ patients; POETIC (Peri-Op-
erative Endocrine Therapy for Individualizing Care) is cur-
rently in its follow-up period [48]. In POETIC, patients were
randomised to receive either no treatment or 2 weeks of
treatment of an AI both before and after surgery with one
aim being to determine biomarkers of response and resist-
ance to oestrogen deprivation. The clinical predictive value of
on-treatment proliferation biomarker Ki-67 levels for long-
term outcome is also being assessed in this trial. Although
short-term reduction in Ki-67 can predict clinical response to
endocrine treatment [49], the accuracy of prediction should
be increased using additional biomarkers. However, before
the introduction of Ki-67 measurement in clinical practice as
an early surrogate marker of treatment efficiency, further
studies for the standardization of measurements, ensuring
reproducibility and consistent scoring, are needed [50, 51]. It
will be several years before the trial matures sufficiently to
fully evaluate how current or potential on-treatment
markers/signatures relate to long-term outcomes.
In a recent window-of-opportunity study, proliferation
genes after treatment were able to accurately predict AI
response at 2 weeks, but not before treatment [52]. Further-
more, a four-gene signature measuring two genes pre-
treatment and two genes after 2 weeks has recently been
shown to predict accurately clinical response to 3 months
of neoadjuvant letrozole treatment in ER+ patients. The test
was also predictive for relapse-free and breast cancer-
specific survival [52]. The genes that predicted response to
AI included two pre-treatment genes associated with
immune response (IL6ST) and apoptosis (NGFRAP1) and
two genes measured after 2 weeks of treatment associated
with proliferation (MCM4 and ASPM). Changes of gene
expression in response to neoadjuvant letrozole treatment
were similar in both invasive ductal and lobular carcinoma
[53]. These observations suggest that transcriptomic
changes that develop during treatment are representative of
the drug’s mechanism of action and independent of the
type of tumour treated, suggesting that suppression of pro-
liferation is the main driver of response. If molecularly and
histologically distinct subtypes are responding in the same
way, then this finding adds to the idea that pre-treatment
differences alone may not define response to treatment,
and that on-treatment changes may be more important.
In a recent neoadjuvant phase II trial with a sequential
biopsy design, the CDK4/6 inhibitor palbociclib given in
combination with anastrozole was shown to be more anti-
proliferative than anastrozole alone by using sequential Ki67
analysis in ER+ cancer [54]. Effects of another CDK4/6
inhibitor, abemaciclib, in combination with anastrozole is
also under investigation in a clinical window-of-opportunity
study with evaluation of change in Ki67 expression from
baseline to 2 weeks (NeoMONARCH phase II trial).
Ribociclib in combination with letrozole for 24 weeks as
neoadjuvant endocrine therapy is also being investigated
(FELINE phase II trial).
The transcriptional response to fulvestrant has also been
investigated in a neoadjuvant study, where a subset of
genes was identified with potential predictive utility to dif-
ferentiate fulvestrant response from oestrogen deprivation
by anastrozole [55]. Transcriptional differences overlapped
with the drugs’ distinct mechanisms of action. In addition
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to inhibition of common oestrogenic ER activity, fulves-
trant was shown to antagonise oestrogen-independent ER
activity with significantly differentiated genes in ER, an-
drogen receptor (AR), and TP53 signalling.
Long-term monitoring of endocrine treatment
response
Although analysing single or sequential breast tumour
biopsy samples may help to estimate individual respon-
siveness before starting treatment, it is not likely that they
will predict continued response or emergence of resist-
ance. Another concern of sampling the tumour only at
diagnosis is that the sampled portion may not reflect any
intra-tumour heterogeneity [46], a major challenge to suc-
cessful and individualised cancer therapy. Repetitive and
non-invasive sampling and analyses of CTCs can help to
implement personalized treatments by monitoring drug
response in metastasis-prone breast cancer patients.
It is suggested that drug-resistant subclone(s) may be
present at diagnosis or may emerge during the treatment
leading to breast cancer metastasis [56]. Functional rele-
vance of the intra-tumour heterogeneity in ER+ breast can-
cer has been demonstrated in a number of recent studies.
In ER+ metastatic patients, two somatic mutations within
the ligand-binding domain of ER were determined and
these mutations were not detected in primary or treatment-
sensitive tumours indicating their emergence during endo-
crine treatment [57]. Acquired ESR1 mutations detected in
metastatic advanced breast cancer patients that are primar-
ily found in ligand-binding domain and leading to constitu-
tive ER activity have been recently reviewed [58]. Although
their role in metastasis has not yet been confirmed,
resistance-associated mutations may be predictive markers
and also potential new targets in metastatic disease.
Whether they are present at the diagnosis or emerge
under the pressure of treatment, resistant clones need to
enter the circulation to cause disease progression. Based
on this, monitoring of CTCs that will eventually give rise
to recurrences and circulating tumour DNA (ctDNA) may
help to overcome therapeutic failure through emergence
of resistant clones.
Circulating tumour cells
Recently, the clinical utility of CTC count in prognostica-
tion of metastatic breast cancer patients has been analysed
by pooling of data from 1944 patients and 20 studies [59].
Both baseline CTC count and decline at 3–5 weeks after
the start of treatment improved survival prediction when
added to the clinicopathological models, confirming the in-
dependent prognostic effect of CTC count on progression-
free survival and overall survival. In addition to its prog-
nostic value, CTC count was also proposed to be an indica-
tor of chemotherapy and endocrine therapy efficacy in
metastatic breast cancer patients [60]. Determination of
treatment response regardless of drug used is possible with
monitoring real-time changes in CTC count.
In addition to CTC count, molecular profiling of CTCs
may provide predictive signatures in patients with breast
cancer. Characterization of CTCs using different molecular
assays such as whole-genome analysis may shed light on
tumour heterogeneity and therapy resistance [61]. However,
there are some limitations to be overcome before their
introduction as clinical tools. In addition to a lack of stan-
dardized methods for their harvest, another limitation is
that some of the surface markers used to isolate CTCs that
are already in low concentrations in plasma, such as E-
cadherin, have been shown to be downregulated during
epithelial-mesenchymal transition (EMT) of breast cancer
[62], making their detection more difficult. Furthermore,
mesenchymal cells were shown to be highly enriched in
CTCs in contrast to primary tumours [63], indicating the
importance of taking account of heterogeneity of CTCs in
the therapeutic follow-up of metastatic breast cancer.
Current CTC capture methods based on epithelial markers
may have limited clinical value since they cannot detect
malignant mesenchymal CTCs. The only FDA-approved
CTC detection system, the CellSearch® CTC Test, counts
only epithelial (EpCAM-positive) CTCs indicating the need
for novel technologies with improved clinical utility
allowing detection and characterisation of different CTCs
subpopulations such as CTCs in EMT [64]. The heterogen-
eity of mutational status of CTCs isolated from the same
breast cancer patient [65] also indicates the necessity of
characterizing CTCs at the single-cell level.
Circulating tumour DNA
Screening cell-free ctDNA released from dying tumour
cells into the bloodstream is another potential, non-
invasive way to monitor the progression of cancer. ctDNA
and CTCs are different in their sensitivity; ctDNA has
been suggested to be a more sensitive measure for re-
sponse prediction in metastatic patients [66]. In addition,
ctDNA was present in the plasma of patients without any
detectable CTCs and they were also detectable in half of
patients with localised breast adenocarcinoma [67]. On
the other hand, ctDNA and CTCs give different informa-
tion regarding the primary and metastatic tumour cells.
CTCs provide an overall picture of cancer cells at the
RNA, DNA, and protein levels, whereas the detection of
genetic and epigenetic alterations including acquired mu-
tations in cancer DNA is possible by analysing ctDNA.
One outcome of the ongoing PIKTAM study, investigat-
ing buparlisib in combination with tamoxifen, is to valid-
ate a technology for sensitive and specific detection of
mutations in circulating free tumour DNA that may help
towards the establishment of a clinical role for ctDNA.
Mutation tracking using serial follow-up ctDNA samples
may identify early breast cancer patients with high relapse
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risk in addition to the use of this genetic information of
residual tumour for tailoring of adjuvant therapy [68].
Monitoring ESR1 mutations using ctDNA potentially allow
the discontinuation and replacement with other treatments
of ineffective endocrine therapies and the prevention of
metastatic disease [69]. For instance, serial analysis of ctDNA
of a patient revealed that ESR1 mutation was detected fol-
lowing subsequent AI treatment, suggesting selection of mu-
tant clones during metastatic therapy, but PIK3CA mutation
was already present before drug exposure [70] which may
help to select metastatic patients for ESR1 mutation-targeted
therapy. The BOLERO-2 trial demonstrated that ESR1 mu-
tations, which promote ligand-independent receptor activa-
tion and resistance to endocrine therapy, were prevalent in
ctDNA from baseline plasma samples of AI-treated ER+
metastatic patients and were associated with shorter overall
survival [71]. Advanced breast cancer patients with baseline
ESR1 mutations treated with fulvestrant have been shown to
have improved outcomes compared with exemestane [72].
However, in a recent retrospective study, serial analysis of
ctDNA did not show any evidence for accumulation of ESR1
mutations during fulvestrant treatment, and progression-free
survival was not different in patients with ESR1 mutations
[73]. Further studies are needed to determine the heterogen-
eity and potential clinical significance of ESR1 mutations
following different drug therapies for better stratification of
patients with advanced disease.
In addition to mutational changes, the methylation status
of ctDNA may help to monitor treatment efficacy in breast
cancer. Although data for neoadjuvant endocrine therapy
are not available yet, a number of studies have reported the
role of ctDNA in monitoring response to neoadjuvant
chemotherapy. Total methylation of a panel of five genes,
BRCA1, MGMT, GSTP1, Stratifin, and MDR1, was
significantly correlated with tumour volume reduction in
responders to neoadjuvant chemotherapy [74]. Also, in
patients with methylation in the promoter region of
RASSF1A before therapy, methylated ctDNA has been
shown to be decreased early following neoadjuvant chemo-
therapy in responders, but non-responders had persistent
methylation levels [75, 76].
The data obtained from circulating blood biomarkers and
before the initiation of metastasis will be more valuable than
the data from metastatic tumours in the management of
metastasis, because the detection and analyses of CTCs and
ctDNA with metastasis-initiating potential in different sites
will provide more comprehensive real-time data. Therefore,
CTCs and ctDNA have the potential to enable prevention
of disease recurrence in addition to individualised treatment
of metastatic patients. Although their clinical relevance in
breast cancer has not been established, there are large num-
ber of ongoing clinical trials and growing evidence support-
ing their role in personalized treatment decisions. Drugs
currently in the clinic are mainly anti-proliferative and
suppress proliferation of subclones. Identification of new
pathways using blood biomarkers may lead to new, more
efficient treatments for metastatic disease.
Future perspectives
Recent studies offer hope that sequential analysis of breast
cancers from patients will lead to more accurate predic-
tions of which patients will benefit from treatment with
existing, combinations, or enhanced endocrine agents. As
tumour cells evolve over the course of treatment, we
should also evolve our treatment approaches based on
mutational and expressional changes acquired by individ-
ual tumours over time. Expansion of studies of neoadju-
vant treatment and monitoring CTCs offer great promise
in predicting response to treatment and disease progres-
sion, and should allow optimal clinical management of
emergence of treatment resistance. After overcoming the
associated technical difficulties, their clinical utility in
monitoring continued endocrine response can be realised.
Conclusions
Future endocrine treatment response prediction tools will
necessitate integration of a wide range of molecular infor-
mation, including gene expression and acquired mutations,
each of which are able to affect drug response. We suggest
that a combined approach including biopsy profiling in the
neoadjuvant setting as well as liquid biopsy profiling should
be used to match effective drugs with individual patients
and to monitor continuation of drug effectiveness.
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